These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 22609455

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):580-95. PubMed ID: 18398104
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.
    Blood; 2015 Jul 16; 126(3):363-72. PubMed ID: 26045609
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma.
    Liu M, Tu J, Feng Y, Zhang J, Wu J.
    J Nanobiotechnology; 2020 Aug 18; 18(1):114. PubMed ID: 32811502
    [Abstract] [Full Text] [Related]

  • 16. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.
    Clin Cancer Res; 2011 Sep 15; 17(18):5973-81. PubMed ID: 21821698
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M.
    Int J Cancer; 2007 Dec 01; 121(11):2387-94. PubMed ID: 17688235
    [Abstract] [Full Text] [Related]

  • 20. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S.
    PLoS One; 2013 Dec 01; 8(11):e78570. PubMed ID: 24223823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.